Table 3.

Secondary efficacy outcomes—adjusted treatment group mean value differences for change from baseline to week 8 (primary estimand, full analysis set)

Comparison	Scale	Active treatment mean, 95% CI	Placebo mean, 95% CI	Adjusted mean value difference, 95% CI	p
Silexan vs. placebo	BDI-II	−10.06 [−11.36; −8.76]	−8.48 [−9.82; −7.13]	−1.58 [−3.38; 0.22]	0.085
	CGI-1	−0.95 [−1.11; −0.80]	−0.78 [−0.94; −0.62]	−0.18 [−0.39; 0.04]	0.111
	CGI-2	2.51 [2.32; 2.70]	2.72 [2.52; 2.91]	−0.21 [−0.47; 0.06]	0.127
	PHQ-9	−5.1 [−5.77; −4.42]	−4.26 [−4.95; −3.57]	−0.84 [−1.77; 0.09]	0.077
	SDS	−6.07 [−7.03; −5.10]	−3.67 [−4.68; −2.65]	−2.40 [−3.76; −1.04]	< 0.001
Sertraline vs. placebo	BDI-II	−10.84 [−12.13; −9.54]	−8.41 [−9.75; −7.07]	−2.43 [−4.23; −0.63]	0.008
	CGI-1	−1.04 [−1.19; −0.89]	−0.79 [−0.94; −0.63]	−0.25 [−0.46; −0.04]	0.020
	CGI-2	2.37 [2.18; 2.56]	2.74 [2.55; 2.94]	−0.37 [−0.63; −0.11]	0.006
	PHQ-9	−5.42 [−6.05; −4.79]	−4.18 [−4.83; −3.53]	−1.24 [−2.12; −0.36]	0.006
	SDS	−4.35 [−5.39; −3.31]	−3.54 [−4.60; −2.47]	−0.82 [−2.26; 0.63]	0.267

CI confidence interval, BDI-II Beck depression inventory (revised), total score, CGI-1 clinical global impressions, item 1 (Severity of Illness), CGI-2 clinical global impressions, item 2 (Global Change), PHQ-9 patient health questionnaire, total score, SDS Sheehan disability scale, global impairment score